Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte Q4 revenue rises 21% to $118.6 million; French unit may enter bankruptcy

Mixed Impact 4 of 5 earnings Written later

Veracyte reported fourth-quarter 2024 revenue up 21% to $118.6 million and full-year 2024 net income of $24.1 million, compared with a net loss in 2023. The company is considering ending funding for its French subsidiary, Veracyte SAS, which could lead to bankruptcy proceedings after a works council consultation unless a buyer is found, and it is not providing total company revenue guidance for 2025.

Key points

  • Q4 2024 total revenue $118.6 million, up 21%; testing revenue $112.2 million, up 24%
  • Q4 2024 net income $5.1 million, diluted EPS $0.06; full-year 2024 net income $24.1 million, diluted EPS $0.31
  • 2025 testing revenue guidance $470 million to $480 million; no total revenue guidance due to Marseille, France uncertainty
  • Veracyte SAS may begin bankruptcy proceedings after works council consultation if no funding or buyer is identified

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECFeb 24, 2025, 4:11 PM ET
Accession number0001384101-25-000010

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 24, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.